Vistagen Therapeutics, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Vistagen Therapeutics, Inc.'s yearly results (2023–2026), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Cash Cushion Ratio: Cash, after subtracting all debt, is 5.3 times its market value (net cash). Higher than almost all Healthcare companies in United States.
- Debt Due Cover Ratio: Operating cash was negative last year, while some debt falls due within a year. Lower than 97% of Healthcare companies in United States.
- Self-Funding Ratio: Over the last 3 years operating cash was negative while the company kept spending on investment (capex). Lower than 94% of Healthcare companies in United States.
Cash quality
Profit Cash Ratio
—Loss-making or profit too small
Over the last 3 years profit was a loss or under 2% of sales, so cash per 100 of profit is not meaningful.
Self-Funding Ratio
-333.4×Over the last 3 years operating cash was negative while the company kept spending on investment (capex).
Lower than 94% of Healthcare companies in United States.
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
2/3 · 1/3Sales grew in 2 of the last 3 years; profit grew in 1 of 3.
Steadier than 50% of Healthcare companies in United States.
Growth Efficiency Ratio
—Data incomplete
Asset Productivity Ratio
—Data incomplete
Balance-sheet strength
Debt Due Cover Ratio
-692.0×Operating cash was negative last year, while some debt falls due within a year.
Lower than 97% of Healthcare companies in United States.
Cash Cushion Ratio
5.3× cashCash, after subtracting all debt, is 5.3 times its market value (net cash).
Higher than almost all Healthcare companies in United States.
Tangible Assets Ratio
—Data incomplete
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (12)
Vistagen Therapeutics, Inc. made a loss over the last year. Vistagen Therapeutics, Inc. owes $0.31 for every $1 it owns. Vistagen Therapeutics, Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Mar 2026.
P/E ratio
LossVistagen Therapeutics, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
0.34The share price is 0.34 times Vistagen Therapeutics, Inc.'s book value per share, lower than 95% of Healthcare companies in United States.
Market cap
$8 MThe total market value of all of Vistagen Therapeutics, Inc.'s shares at today's price (share price × number of shares), smaller than 89% of Healthcare companies in United States. PosiCap size class: Nano Cap.
Net worth (book value)
$24 MWhat Vistagen Therapeutics, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$0.55Net worth divided by the number of shares. The share price of $0.19 is 0.3 times this, which is the P/B above.
Return on equity (ROE)
-166.5%Vistagen Therapeutics, Inc. lost 166.5% of its shareholders' money over the last year, lower than 81% of Healthcare companies in United States.
Owes vs Owns
0.31×Vistagen Therapeutics, Inc. owes $0.31 for every $1 it owns (low), lower than 59% of Healthcare companies in United States.
Dividend yield
NoneVistagen Therapeutics, Inc. does not currently pay a dividend.
Revenue growth
+161%Revenue rose 161% in the year to Mar 2026.
Profit growth
LossVistagen Therapeutics, Inc. made a loss in each of the last two years.
Profit margin
-5491.3%Vistagen Therapeutics, Inc. lost $5491 for every $100 of revenue.
Cash vs debt
Net cashVistagen Therapeutics, Inc. held $44 M more cash than debt (net cash) at Mar 2026.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Vistagen Therapeutics, Inc.: $8 M ÷ $24 M (30 Jun 2026) = 0.3.
What is Vistagen Therapeutics, Inc.'s return on equity?
Vistagen Therapeutics, Inc. lost 166.5% of its shareholders' money over the last year, lower than 81% of Healthcare companies in United States.
How much does Vistagen Therapeutics, Inc. owe compared with what it owns?
Vistagen Therapeutics, Inc. owes $0.31 for every $1 it owns (low), lower than 59% of Healthcare companies in United States.
Does Vistagen Therapeutics, Inc. pay a dividend?
No. Vistagen Therapeutics, Inc. does not currently pay a dividend.
Is Vistagen Therapeutics, Inc.'s revenue growing?
Revenue rose 161% in the year to Mar 2026.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.